Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Gallium Ga 68 Relitegatide Brexetan · RAD301

Radiopharmaceutical · Acts on integrin alphaVbeta6 (ITGB6) · developed by Radiopharm Theranostics

Phase 1 Most advanced trial
RADX Developer
1 Registered trials

What is Gallium Ga 68 Relitegatide Brexetan?

Gallium Ga 68 relitegatide brexetan is a PET radiotracer made of an integrin alphaVbeta6-binding peptide labeled with gallium Ga 68. The peptide binds integrin alphaVbeta6-expressing cancer cells, allowing their visualization by positron emission tomography. It is studied in pancreatic, lung, esophageal, cervical, endometrial and ovarian cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RAD301
Drug type
Radiopharmaceutical
Targets
integrin alphaVbeta6 (ITGB6)
Mechanism
Acts on integrin alphaVbeta6 (ITGB6)
Pathways
cell adhesion and signaling, tumor cell proliferation, migration and invasion
Therapy area
Oncology
Developer
Radiopharm Theranostics, Ltd (RADX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
56VJ6PVP37

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05799274 Phase 1 Healthy Volunteers Active not recruiting RADX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CancerEndometrial CancerEsophageal Squamous Cell CarcinomaHealthy VolunteersNon-small Cell Lung Cancer (NSCLC)Ovarian CancerPancreatic Ductal Adenocarcinoma

Other drugs acting on ITGB6

More from Radiopharm Theranostics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.

Follow RADX, the company behind Gallium Ga 68 Relitegatide Brexetan

See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RADX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.